A small molecule studied for major depression on a neurogenesis hypothesis; Phase 2 results were mixed and it is not approved.
NSI-189 is a small molecule developed on the 'neurogenesis' theory of depression — the idea that growing new neurons in the hippocampus could relieve mood disorders.
In preclinical models it stimulated hippocampal neurogenesis and even increased hippocampal volume, which is the mechanistic story behind its development as an antidepressant candidate.
In actual human trials, though, the antidepressant results were inconsistent, leaving the link between its proposed mechanism and real benefit unresolved. It is not approved.
Searching the published record…
Searching the published record…
Searching the published record…
Studies are surfaced live from the U.S. National Library of Medicine (PubMed). biohackr indexes and links the published record; it does not host or alter source articles.